AG真人官方

On 29 July 2025, Solaris Resources Inc. (SLSR) submitted a Form 6-K reporting a change of auditor. Three exhibits accompany the filing: (i) 鈥淣otice of Change of Auditor,鈥� (ii) KPMG鈥檚 response letter, and (iii) BDO鈥檚 response letter. While the body of the 6-K provides no financial data, the exhibit titles imply KPMG LLP is the outgoing auditor and BDO is the incoming firm. The report contains no disclosure of disagreements, restatements, or timing details鈥攖hose elements, if any, are expected within the exhibits. The document is signed by CFO & Secretary Richard Hughes, indicating board authorization.

Auditor changes can affect perceived governance quality, audit continuity, and filing timelines; investors should review the attached notices for any 鈥渞eportable events鈥� under PCAOB or Canadian securities rules. Absent further information, the filing is procedural but warrants monitoring until the full rationale and impacts on future financial reporting are clarified.

The Vanguard Group filed Amendment No. 2 to Schedule 13G for Daily Journal Corp. (DJCO). As of the event date 06/30/2025, Vanguard reports beneficial ownership of 100,243 DJCO common shares, equal to 7.27 % of the outstanding class.

Voting power is minimal: 0 shares sole and 1,373 shares shared. Dispositive power is larger, with 97,833 shares sole and 2,410 shares shared. Vanguard files under Rule 13d-1(b) in its capacity as an investment adviser ("IA"), indicating the position is held in the ordinary course of business without the intent to influence control. The certification is signed by Ashley Grim, Head of Global Fund Administration, on 07/29/2025.

The amendment confirms Vanguard remains a >5 % passive institutional holder, providing updated ownership details but no indication of strategic changes or control ambitions.

Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) filed a Form 144 indicating that insider Yury Gryzlov intends to sell 2,000 common shares through Morgan Stanley Smith Barney LLC. The shares are valued at $24,660 and are expected to be sold on 07/08/2025. Gryzlov acquired the shares as restricted stock on 03/13/2021. The company has 84,547,653 shares outstanding, so the planned sale represents only about 0.002 % of the float. During the past three months, the same insider sold an additional 4,737 shares for $59,151.34. No other financial or operational data is provided in this notice.

On 20 June 2025, SNDL Inc. submitted a routine Form 6-K to the U.S. Securities and Exchange Commission.

The filing is primarily administrative and incorporates three exhibits into multiple Form S-8 registration statements:

• Exhibit 99.1: Notice of Meeting and Information Circular (dated 20 June 2025)
• Exhibit 99.2: Form of Proxy
• Exhibit 99.3: Notice-and-Access Notice

The report was signed by General Counsel & Corporate Secretary Matthew Husson. No financial statements, earnings results, or strategic transactions accompany the submission, indicating that the document is a standard compliance update rather than a material event. Consequently, the filing is unlikely to influence near-term valuation or market perception.

Cardiff Oncology, Inc. (CRDF) 鈥� Form 4 filing dated 06/30/2025

The filing discloses that director Rodney S. Markin received 40,565 stock options on 06/26/2025 at an exercise price of $3.16 per share. The options become exercisable on 06/26/2026 and expire on 06/26/2035. The transaction is coded 鈥淎,鈥� indicating an award or grant with no cash paid by the insider. Following the grant, Markin holds 222,865 derivative securities (stock options) directly. No open-market purchases or sales of common stock were reported, and no changes were recorded in Markin鈥檚 non-derivative share ownership.

The grant is a routine equity incentive intended to align the director鈥檚 interests with those of shareholders. Given the modest size relative to Cardiff Oncology鈥檚 total shares outstanding, the transaction is considered immaterial from a dilution standpoint and does not, by itself, signal any change to the company鈥檚 strategic outlook or financial condition.

Form 4 filing overview

On June 23, 2025, GlycoMimetics, Inc. (GLYC) disclosed that director Jonathan Violin received a stock option covering 9,023 ordinary shares at an exercise price of $15.30 per share. The award vests in full on the earlier of June 23, 2026 or the company鈥檚 next annual shareholder meeting, provided he remains in service, and expires on June 23, 2035. The option is held directly by Violin; no open-market purchases or sales of common stock were reported, and Table I shows no changes in non-derivative share ownership.

The filing represents a routine equity incentive grant to a non-employee director. While it increases Violin鈥檚 long-term exposure to the company鈥檚 equity, it does not, by itself, indicate a change in insider sentiment or the firm鈥檚 financial outlook.

Cardiff Oncology director James O. Armitage received a new stock option grant on June 26, 2025. The derivative securities transaction details include:

• Granted 40,565 stock options to purchase common stock
• Exercise price set at $3.16 per share
• Options become exercisable on June 26, 2026
• Options expire on June 26, 2035
• Following this grant, Armitage now beneficially owns 187,539 derivative securities directly

This Form 4 filing represents a standard director compensation stock option grant, which vests one year from the grant date and has a 10-year exercise period. The transaction appears to be part of the company's regular director compensation program rather than an open market transaction.

On 06/26/2025, Cardiff Oncology (CRDF) director Lale White reported the grant of 40,565 stock options at an exercise price of $3.16 under Form 4. The options become exercisable on 06/26/2026 and expire on 06/26/2035. The transaction code "A" confirms the award was acquired rather than purchased on the open market. Following this grant, White now holds 158,681 derivative securities (options) directly. No common shares were bought or sold, and no additional non-derivative activity was disclosed.

This filing appears to reflect routine director compensation designed to align insider incentives with shareholder interests. Because the award involves options鈥攔equiring future exercise鈥攖here is no immediate cash outflow or direct impact on outstanding share count.

Cardiff Oncology, Inc. (CRDF) 鈥� Form 4 Overview

On 06/26/2025, Director Gary W. Pace received a grant of 40,565 stock options with an exercise price of $3.16 per share under the company鈥檚 equity compensation plan. The options expire on 06/26/2035. After the grant, Mr. Pace beneficially owns 187,539 derivative securities (options) in total. The Form 4, filed on 06/27/2025, reports no open-market purchases or sales of common stock, and the holdings are reported as Direct (D) ownership. This filing reflects routine director compensation rather than an investment decision.